ESC 365 - Early benefits of empagliflozin in patients with type 2 diabetes with heart failure are not offset by increased adverse events: results from the EMPA-REG OUTCOME trial

ESC Premium Access

Early benefits of empagliflozin in patients with type 2 diabetes with heart failure are not offset by increased adverse events: results from the EMPA-REG OUTCOME trial

Session: Poster Session 3 - Heart failure: prognosis, outcome

Topic: Pharmacotherapy

Speaker: Doctor P. Pellicori (Glasgow, GB)

Event: ESC Congress 2019

Congress Presentation

Add to my library

About the speaker

Doctor Pierpaolo Pellicori

University of Glasgow, Glasgow (United Kingdom of Great Britain & Northern Ireland)

4 presentations

1 follower

9 more presentations in this session

Diffuse coronary artery disease and effect of implantable cardioverter-defibrillators in patients with non-ischaemic systolic heart failure

Speaker: Doctor C. Byrne (Copenhagen, DK)

Predicting cardiac recovery before durable left ventricular assist device implantation in advanced heart failure patients

Speaker: Doctor S. Drakos (Salt Lake City, US)

Incidence and prognostic impact of new-onset left bundle branch block in patients with heart failure and reduced ejection fraction

Speaker: Professor L. Kober (Copenhagen, DK)

Improved attitudes of non-cardiologists towards decreased left ventricular ejection fraction after marking "warning" on echocardiography report

Speaker: Miss Q. Chen (Chengdu, CN)

Prognosis and predictors for left ventricular reverse remodeling in dilated cardiomyopathy

Speaker: Professor I. Jung (Yongin, KR)

Access the full session

Poster Session 3 - Heart failure: prognosis, outcome

Speakers: Doctor P. Pellicori, Doctor C. Byrne, Doctor S. Drakos, Professor L. Kober, Miss Q. Chen...

About the event

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources